SAKAR HEALTHCARE LIMITED

Investor Presentation | Q2 & H1FY27



Safe Harbor

This presentation and the accompanying slides (the "Presentation"), which have been prepared by **Sakar Healthcare Limited** (the "Company"), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict.

These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company's market preferences and its exposure to market risks, as well as other risks.

The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.



Financial & Operational Performance

Q2 & H1FY27 Operational Highlights


Business momentum	• 69 oncology product contracts executed; 45 commercial discussions currently underway; • Strengthened its global oncology presence in Q2 through portfolio expansion, wider market access across the EU, UK, Canada, APAC and LATAM, and participation in CPHI Worldwide
Tech transfer	• 33 tech transfer projects underway with 4 Partners ; 33 site variations submitted & 11 approved (stringent market-EU & UK) across 18 cytotoxic molecules. • Accord has received 6 more product site variations approval by EMA (total now becomes 8 of 11 molecules) at our oncology site • 3 other site variation approval received from MHRA / EMA. (for 2-partners in the UK and 1 in Germany).
Regulatory approvals	• Shared 351 dossiers globally, of which 191 have been submitted and 22 have received Marketing Authorisations. • The approved MAs are well dispersed globally: Europe & UK-11, Latin America-6, APAC-4, Canada-1 • 36 EU MA applications, of which 16 are own filings;
Backward integration (API)	• 21 APIs developed in-house; 16 with Written Confirmation; 8 commercialised; 2 of 7 CEP applications approved, 5 currently under process • Commercial supplies to domestic & International Markets has started from the API-integrated, EU GMP-approved oncology FDF site
General update	• Cancer coverage widened to breast, lung, prostate, stomach, head & neck, colorectal, ovary, liver, kidney, thyroid, blood, bone-marrow and lymph • Sakar is moving towards an integrated, regulatory-driven business model, with greater value-chain integration improving supply-chain control, margin visibility and scalability.


Q2 & H1FY27 – Consolidated Financial Highlights

INR in Lakhs


Sakar Healthcare Ltd.


Revenue







EBITDA





PAT





Q2 & H1FY27 – Consolidated Profit & Loss Statement

Sakar Healthcare Ltd.

Particulars (INR in Lakhs)	Q2 FY27	Q2 FY26	Y-o-Y	Q1 FY27	Q-o-Q	H1FY27	H1FY26	Y-o-Y
Revenue from Operations	8,741.61	5,756.04	**52%**	7,297.25	**20%**	16,038.86	11,029.66	**45%**
COGS	4,573.56	3,040.64		3,458.22		8,031.78	5,935.88	
Gross Profit	**4,168.05**	**2,715.40**	**53%**	**3,839.03**	**9%**	**8,007.08**	**5,093.78**	**57%**
Gross Profit Margin (%)	**48%**	**47%**		**53%**		**50%**	**46%**	
Employee Expenses	976.16	834.19		1,145.51		2,121.67	1,589.15	
Other Expenses	757.36	745.82		568.63		1,325.99	1,098.66	
EBITDA	**2,434.53**	**1,135.39**	**114%**	**2,124.89**	**15%**	**4,559.42**	**2,405.97**	**90%**
EBITDA Margin (%)	**28%**	**20%**		**29%**		**28%**	**22%**	
Other Income	28.13	121.46		154.39		182.52	160.85	
Depreciation	660.22	568.38		654.24		1,314.46	1,125.61	
Finance Cost	200.40	152.68		166.97		367.37	366.94	
Profit before Tax	**1,602.04**	**535.79**	**199%**	**1,458.07**	**10%**	**3,060.11**	**1,074.27**	**185%**
Profit before Tax(%)	**18%**	**9%**		**20%**		**19%**	**10%**	
Tax	471.35	81.81		429.58		900.93	153.16	
Profit After Tax	**1,130.69**	**453.98**	**149%**	**1,028.49**	**10%**	**2,159.18**	**921.11**	**134%**
PAT Margin (%)	**13%**	**8%**		**14%**		**13%**	**8%**	
Basic EPS (As per Profit after Tax)	5.08	2.03		4.62		9.70	4.14	

Q2 & H1FY27 – Consolidated Balance Sheet

Particulars (INR in Lakhs)	Sept 26	Mar 26
ASSETS		
Non-Current Assets		
Property, Plant and Equipment	32,089.98	31,905.90
Capital work-in-progress	576.76	396.53
Other Intangible Assets	1,268.32	742.70
Non Current Financial Assets	30.06	30.06
Other Non Current assets	1,548.78	979.90
Total Non - Current Assets	**35,513.90**	**34,055.09**
Current Assets		
Inventories	9,720.52	7,004.14
Current Financial Assets		
(i) Trade Receivables	3,940.87	5,008.33
(ii) Cash and Cash Equivalents	4.78	4.21
(iii) Bank balance	21.75	21.75
Current tax asset (net)	2,371.11	2,007.42
Total Current Assets	**16,059.03**	**14,045.85**
Total Assets	**51,572.93**	**48,100.94**

Particulars (INR in Lakhs)	Sept-26	Mar-26
Equity		
Equity Share Capital	2,224.99	2,224.99
Other Equity	32,374.12	30,220.26
Total Equity	**34,599.11**	**32,445.25**
Liabilities		
Non-Current Liabilties		
Financial Liabilities		
(i) Borrowings	3,301.14	3,135.30
Deferred Tax Liabilities (net)	1,392.57	1,285.82
Provisions, Non current Liablities	288.25	280.84
Total Non-Current Liabilities	**4,981.96**	**4,701.96**
Current Liabilities		
Financial liabilities		
(i) Borrowings	1,300.98	2,395.09
(ii) Trade Payables	6,225.06	5,154.00
(iii) Other Current Financial Liabilities	1,613.00	1,523.00
Other Current Liabilities	1,969.77	1,017.45
Current Tax Liabilities (Net)	883.05	864.19
Total Current Liabilities	**11,991.86**	**10,953.73**
Total Equity and Liabilities	**51,572.93**	**48,100.94**

Q2 & H1FY27 – Consolidated Cash Flow Statement

Cash Flow Statement (INR in Lakhs)	H1FY27	H1FY26
Profit before Tax	3,060.11	1,074.27
Operating Profit before Working Capital Changes	**4,676.45**	**2,552.98**
Changes in Working Capital	-2,178.86	784.26
Cash Generated from Operations	**2,497.59**	**3,337.24**
Less: Direct Taxes paid	-151.95	-278.53
Net Cash from Operating Activities	**2,345.64**	**3,058.71**
Cash Flow from Investing Activities	-2,204.39	-2,739.95
Cash Flow from Financing Activities	-140.68	-328.08
Net increase/ (decrease) in Cash & Cash equivalent	**0.57**	**-9.32**
Add: Cash and cash equivalents as at beginning of the period	4.21	10.16
Cash and cash equivalents as at end of the period	**4.78**	**0.84**

Sakar Healthcare Ltd.



Company Overview

From Vision to Value: Sakar Healthcare at a Glance

- Founded by **Mr. Sanjay Shah**, Sakar Healthcare has evolved from a contract manufacturer into an **API-integrated pharmaceutical organization** with a strong presence across **oral solids, injectables, and oncology formulations**.
- Over two decades, the company has built a reputation for **credibility, compliance, and precision**, supported by world-class **WHO and EU-GMP certified facilities** in Gujarat and a global network of partnerships across regulated markets.
- The establishment of a **state-of-the-art oncology facility at Bavla**, equipped with integrated **API and FDF capabilities**, marks a defining milestone in Sakar's transformation. This expansion elevates the company from a reliable formulation partner to a **vertically integrated player** in the global oncology space — combining **scientific innovation, scalable manufacturing, and sustainable operations**.
- As it enters its next phase of growth, Sakar Healthcare stands positioned for **onco-led value creation**, leveraging its legacy of quality and research excellence to deliver **specialized, high-compliance healthcare solutions worldwide**.



292+
Product Registrations MAs

300+
Dossiers filed (in process)

75+
International Partners Network

60+
Country Presence (Emerging Markets)

25+
Therapeutic Segments Coverage

55
Oncology Molecules Development to Launch

Board of Directors

Sanjay Shah
Promoter, Chairman & Managing Director

Founder-promoter with over decades of cross-industry experience, leading the Company's strategy, operations, and growth initiatives.

Aarsh Shah
Promoter, Joint Managing Director

Pharmacist and UK-educated MBA spearheading production, international sales, and global customer relationships.

Sunil Marathe
Whole-time Director – Technical

Technical professional with a Master's degree in Organic Chemistry and 30+ years of industry experience, supporting manufacturing and quality operations.

Visalakshi Chandramouli
Non-Executive Director

Provides independent oversight and strategic guidance at the board level.

Jignesh Parikh
Independent Director

HVAC expert with extensive experience in pharmaceutical manufacturing facilities including Onco, Hormonal, and Beta plants.

Khyati Shah
Independent Director

Company Secretary and legal professional with over five years of experience in finance, secretarial, and compliance matters.

Megha Samdani
Independent Director

Company Secretary with expertise in mergers, capital raising, and financial restructuring.

Hiral Patel
Independent Director

MBA (Finance) with over seven years of experience across finance, banking, taxation, and legal domains.

Reeya Kothari
Independent Director

Company Secretary with hands-on experience in taxation, legal, and secretarial functions

Leadership Team that Drives Growth





EU GMP APPROVED

HIGH POTENT ONCOLOGY OSD (Tablet, Capsule, Granule)
HIGH POTENT ONCOLOGY INJECTION (Liquid, Lyophilised)
GENERAL SMALL VOLUME PARENTERAL (Liquid, Lyophilised)

Sakar is at crux of next phase of growth, prepared to enter the niche segment of Oncology to cater to humanity. Sakar is well equipped to deliver High Precision Research works, suitably followed by Technology Transfer and Scale-up to commercialize Anti-Cancer products worldwide."



Mr. Sanjay Shah
Chairman & MD



Mr. Aarsh Shah
JT. MD



Mr. Sunil Marathe
Technical Director



Mr. Dharmesh Thaker
CFO



Mr. Bikramjit Ghosh
VP-Strategy & Business Development

Vision, Mission & Values

Sakar Healthcare Ltd.

Vision

To become a global healthcare organization based on three pillars- people, partnership and performance; making lives healthy happy and more meaningful by providing world class healthcare solutions.

Mission

To strengthen our core competencies to become the preferred choice in existing partnerships and explore new market opportunities to expand range of products and services- respecting laws, protecting environment and benefitting mankind

Values

Committed team

Loyal to partners

Focused on results

Innovative approach

Diversified Model

Sakar Healthcare operates a diversified business model comprising **CDMO Services, Own Brand Exports and Product Development Technology Transfer** enabling a balance between stability and strategic growth.

CDMO / CMO Services

Sakar Healthcare provides **Contract Development and Manufacturing (CDMO/CMO)** services to leading multinational and dstic pharmaceutical companies. The company's integrated setup enables product development, scale-up, and regulatory dossier support under global compliance standards. This vertical ensures consistent capacity utilization and steady recurring revenues.

Own Brand Exports – The Growth Driver

Sakar markets its own branded formulations across **60+ countries**, building brand equity and higher-margin revenue streams. The company's global footprint spans **APAC, Latin America, Africa, CIS, and Europe**, positioning it as a preferred partner in both branded and generic markets.

Licensing / Product Development

Sakar Healthcare co-develops product under **patent non-infringing** set and **effect Technology Transfer** or scale up to commercial batches based on partner requirements. Sakar License out developed CTD dossiers.

Sakar's Go-To Market Strategy

Sakar Healthcare Ltd.

MODELS	Licensing & Supply Agreement	Contract Development / Research & Manufacturing Service	Contract Development/ Manufacturing Service	MAH & Distribution	Profit Sharing	Co-development & Technology transfer
MARKETS	EU and the UK	MENA	AFRICA	LatAm and Canada	APAC	CIS
PRODUCTS	Oncology Oral solids	Oncology Oral liquids	Oncology liquid injections	Oncology Lyophilized Injection	Oncology bulk drug	Oncology API

A Differentiated Solutions Provider

Sakar Healthcare Ltd.

Platform Integration

EU-GMP certified oncology FDF facility with integrated API

Ready EU CTD dossiers with 22 global Marketing Authorizations granted

First patent received; APIs developed with 16 written regulatory confirmation



Pipeline Strength

55 oncology molecules developed; 32 dossiers ready for launch

Developing Liposomal (Doxorubicin) & HME products (Apalutamide, Olaparib, Enzalutamide)

Focused on development of non-infringing patent formulations for regulated markets

Profitability & Partnerships

Diversified model: LSA, CDMO, CRAMS, tech transfer, profit sharing

Oncology delivers ~2x higher margins vs. general formulations

Shift towards own brand exports (70%) enhancing profitability

Purpose & Technology

Advanced Flow Chemistry (Vapourtech, UK) and GEA granulation lines

Toffolo lyophilizes, Di-Dietrich glass reactors ensure global compliance

Green Chemistry, ZLD & solar systems driving sustainable manufacturing


Trusted by Pharma Leaders

Sakar Healthcare Ltd.

ZYDUS LIFESCIENCES LIMITED	TORRENT PHARMACEUTICALS LTD.	HEUMANN PHARMA	MERCK LIMITED
INTAS PHARMACEUTICALS LTD.	ACCORD HEALTHCARE LTD.	EMCURE PHARMACEUTICALS LIMITED	TILLOMED LABORATORIES LTD.
ABBOTT INDIA LTD.	INDOCO REMEDIES LIMITED	USV LTD.	CADILA PHARMACEUTICALS LTD.
BAXTER	PHAROS PHARMACEUTICAL	STRIDES ARCOLAB LIMITED	CIPLA LIMITED.
IPCA LABORATORIES LTD.	WOCKHARDT LTD.	GLENMARK PHARMACEUTICALS LIMITED	FERRING PHARMACEUTICALS

Our Long-Standing Client Association

Years




Sakar
Healthcare Ltd.
Oncology – The Future with Sakar

Oncology – the driving growth engine

Oncology lies at the core of Sakar Healthcare's transformation. As the global cancer burden continues to rise, the need for safer, more accessible, and effective therapies has never been greater.

With the growing prominence of biologics, cytotoxic, and complex generics, oncology presents one of the most compelling opportunities in pharmaceuticals—defined by high entry barriers, limited competition, and superior profitability.

For Sakar, entering the oncology space is not merely a business expansion—it represents a deliberate shift toward value-driven innovation and scientific purpose. Our EU-GMP approved Bavla facility, equipped with integrated API and FDF capabilities and advanced flow chemistry systems, enables seamless progression from research to commercialization under one roof.

Oncology in Indian Pharmaceutical landscape


Rising cancer incidence - Cancer already causes more than 26,000 deaths every day, with an estimated 20.6 million new cases and nearly 10 million deaths annually,

CAGR- The global oncology drugs market size was valued at USD 256.46 billion in 2025. The market is projected to grow to USD 697.59 billion by 2034.


Government support for oncology research is strengthening through increased funding, clinical research programmes

Market growth is accelerating, as premium therapies expand into early-stage cancer treatment, improving cure rates and reducing recurrence risk

Global Oncology Market (USD Bn)



Indian Oncology Market (USD Bn)



Source – Fortune business insights, imarc, UN.org

Sakar Oncology - Building the Future of Cancer Care

A research-driven, API-integrated, EU-GMP approved oncology FDF unit. Empowering global access to high-potency cancer therapies through precision research, advanced manufacturing, and sustainable innovation.

Strategic Overview

Facility:

- **Bavla, Gujarat** – EU-GMP approved, vertically integrated oncology plant
- **Product Capability**: Oral solids, oral liquids, sterile injections (liquid & lyophilised), and oncology APIs (De-Dietrich glass reactors for complex oncology molecules)
- **R&D Excellence**: Integrated F&D, ADL, and R&D labs equipped with Flow Chemistry (Vapourtec, UK)
- **Innovation Focus**: Liposomal, HME-based, and cytotoxic oral liquid formulations to enhance patient compliance and bioavailability

Portfolio Strength:

65 oncology products developed in-house

32 ready for global launch

22 Marketing Authorisations (MAs) granted in EU and worldwide

Annual Production

APIs – **12.3 MT**

Oral solids – **97 million tablets, 29 million capsules**

Sterile injectables – **13 million vials**
Lyophilised – 22,000 vials per cycle (10 ml)

Key Differentiators

Vertically integrated from API to Finished Dosage	High containment (OEL Level 4) facility ensuring safety and compliance	Green Chemistry adoption for energy efficiency and waste reduction	Technology Transfer & Scale-Up ready labs supporting CRAMS, CDMO, & co-development models	In-house EU-CTD dossier preparation with bioequivalence studies from EMA/USFDA-approved CROs

Liquid / Lyophilised Injectable Unit - Oncology

Manufacturing Capacity (Cytotoxic injections)

Container Size	Capacity Per Hour
2ml to 10 ml	7200
20ml / 30 ml	3000

Lyophilized Product Capacity

Container Size	Capacity / Cycles
10 ml	22000 Vials



Significance of the Unit

Eurovent certified AHU

Water system-two pass RO with EDI

ETP (zero-discharge)

Oral Solid Unit - Oncology

Manufacturing Capacity (Cytotoxic OSD)

ORAL SOLID UNIT - Oncology	Capacity
Bulk Drug	6.5-120kg/Shift
Tablet	324000 tablets/Shift
Capsule Filling	96000 capsules/Shift
Blister Packing	324000 tablets/Shift
Bottle Packing	324000 tablets/Shift





EU-GMP Approved Oncology OSD Unit

The facility meets European regulatory standards, reflecting global manufacturing compliance. Its design allows seamless scale-up from pilot to commercial batches, reducing technology transfer challenges. This ensures faster market entry and reliability in regulated supply chains.

Containment and Isolation Systems for OEL Compliance

Operations are performed in fully contained suites to safely handle high-potent APIs.
The setup maintains operator and environmental protection, achieving required OEL standards upto level 4. Such containment capability differentiates Sakar as a trusted oncology manufacturer.

Fully Automatic Line with Global Machinery Integration

The plant features automated operations from granulation to final packing.
Equipment sourced from GEA, Glatt, IMA, ACG, and Sejong ensures consistency and quality precision. This high degree of automation minimizes human intervention and product variability.

Oral Liquid Oncology Section with Advanced Compounding

Includes a 500L compounding vessel equipped with an in-line homogenizer and filtration system. The system supports viscous and sensitive oncology liquids, maintaining uniformity and stability. This adds flexibility to Sakar's oncology portfolio by covering both solid and liquid dosage forms.

Product Development Snapshot

Sakar Healthcare Ltd.

Oral Solids	Injection	APIs	Liquid orals
22 products developed	21 products developed	21 APIs developed	12 products developed
16 EU CTD dossiers	16 EU CTD dossiers	16 with Written Confirmation	
9 products in pipeline	9 products in pipeline	7 applied for CEP (Received approval - 2)	

- 11 Bio-study completed from EMA / US FDA approved CROs
- RLD's are from EU

Business Spread

Business Contracts

60+

Overseas Business contracts

25

Europe (LSA & CMO)

44

Rest Of World

Dossier Status

261 ▸ 351

QoQ change in dossiers shared

178 ▸ 191

QoQ change in dossiers submitted

16 ▸ 22

QoQ change in MAs granted

Domestic Supply Partners

15

Active partners

19

API supply partners with **8** products

Business plan in 2 years



100+
Overseas Business contracts

300+
Dossier approval

20+
Domestic partners

19
(9 products) API supply partners


Sakar Healthcare Ltd.



Industry Overview & Growth Drivers

Industry Overview


Global Pharmaceutical Market (In US$ Billion)



Global pharmaceutical manufacturing is projected to grow from **USD 549 billion in 2026 to USD 882 billion by 2031** growing at a **CAGR 9.93%**

Over **USD 300 billion** invested in greenfield and brownfield capacity expansion between 2024 and early 2026 signals strong industry momentum toward a more advanced, resilient and scalable pharmaceutical manufacturing landscape.

Indian Pharmaceutical Market (US$ billion)



India's pharmaceutical market is projected to grow from **USD 60.3 billion in 2026 to USD 79.7 billion by 2031** growing at a **CAGR of 5.74%.**

The growth curve is underpinned by patent expiries that widen the generic pipeline, government production-linked incentives that bolster active pharmaceutical ingredient capacity, and a rapid rise in chronic diseases that ties patients to multi-year therapy plans.

Source: Mordor intelligence

Industry Growth Drivers



01 Ageing Population & Chronic Disease Burden

Over 1 in 6 people globally will be aged 60+ by 2030, driving demand for long-term care and chronic treatments.

02 Shift Toward Value-Based & Preventive Care

Increasing adoption of data analytics and personalized medicine to improve outcomes and reduce costs.

03 R&D and Innovation Focus

The rising emphasis on research and development of advanced therapies by key players operating in the market also supports market growth.

04 Government & Policy Support

Initiatives improving access, insurance coverage, and manufacturing incentives in emerging markets like India.

05 Growing CDMO/CRAMS Partnerships

The market size was valued at USD 199.27 billion in 2025 and is projected to grow to USD 419.93 billion by 2034, exhibiting a CAGR of 8.7%.

06 Sustainability & Green Manufacturing

Industry shift toward eco-friendly and zero-discharge production systems for global compliance.

Source: WHO, Fortune business insights

Green Chemistry – Engineering Sustainability

Sakar Healthcare Ltd.

Green Chemistry 12 Principles

1 Prevent waste	2 Maximize atom economy	3 Less hazardous chemical syntheses	4 Safer chemicals & products	5 Safer solvents & reaction-conditions	6 Increase energy efficiency
Minimize potential for accidents 12	Analyse in real time to prevent pollution 11	Design chemicals & products to degrade after use 10	Use catalysts 9	Avoid chemical derivatives (protein groups) 8	Use renewable feedstocks 7

Vapourtec R Series System, UK	Glass Line Reactors from De-Dietrich, Italy	OSD Containment Granulation and Compression Line, GEA, Belgium	Glatt-Autocoater, Germany	Tablet Capsule Inspection Machine by Sensum, Slovenia	Sterile Manufacturing Line with Lyophiliser, Tofflon	Kevin Roll Compacter	Bulk packaging Line IMA, Germany


Enables Green Chemistry

Adopted techniques like Flow-Chemistry (Vapourtech) - safer with small reaction volumes, low solvent-reagent, low risk of environment exposure

Containment manufacturing-lines or Isolators in place to support Green Chemistry principles


Designs and processes are in place to suit Green Chemistry objectives

Newly installed facility along with world class equipment, provides Sakar competitive edge



Key Investment Proposition

Sakar Healthcare Ltd.





Manufacturing Prowess

Liquid / Lyophilised Injectable Unit (Vials and Ampoules)

Sakar Healthcare Ltd.

Manufacturing Capacity (SVP)

Ampoules	1ml & 2ml	18000
	3ml	16000
	5ml	14000
Vials	2ml	18000
	5ml & 10ml	15000
	20ml & 30ml	12000



30+
No. of Products in the Category

Manufacturing Capacity Lyophilised

Vials	10ml	22000

Significance of the Unit

- Sublimation based lyophilization improves product shelf life and reconstitution quality.
- Handles both liquid and lyophilized injectables under one roof
- Equipped with Tofflon lyophilizer and ORABS technology – freeze drying with autoloading and unloading
- HEPA filtered Class 100 environment ensures aseptic processing

Cephalosporin - Oral Solid Unit (Tablets, Capsules, Dry Syrups & Sachets)

Sakar Healthcare Ltd.

Manufacturing Capacity

Process	Capacity (kgs/shift)
Granulation	500 Kgs/shift
Blending	1000 kgs /shift
Compression	1200000/shift
Filling	1200000/ shift
ALU- ALU packing	1200000/ shift
ALU- ALU packing	600000/shift
Dry Syrup	25000/shift



40
No. of Products in the Category

Significance of the Unit

Core hub for oral solids with wide dosage flexibility (80–1500 mg tablets, 250–500 mg capsules).

Fully automated line from granulation to packing, minimizing contamination and material loss.

Offers packaging versatility – ALU-ALU, ALU-PVC, strip & dry syrup – suited for diverse market needs.

HEPA-filtered environment with controlled storage ensure

Cephalosporin – Injectable Unit (Dry Powder)

Sakar Healthcare Ltd.

Manufacturing Capacity

Container size	Capacity (per Hour)
250 mg	14400
500 mg	14400
1 gm / 2 gm	11500
3 gm / 5 gm	8500



18
No. of Products in the Category

Significance of the Unit

Key sterile block for antibiotic dry powder vials (250 mg to 5 g range).

Ensures aseptic integrity with HEPA-controlled environment and segregated flows.

High-speed visual inspection (15,000 vials/hour) and automated packaging ensure quality and efficiency.

Controlled storage with humidity regulation maintains product stability and compliance

Oral Liquid Unit (Syrup & Suspension)

Sakar Healthcare Ltd.

Manufacturing Capacity

Volumes	No of bottles/ Shift
10 ml	75000
30 ml	75000
60 ml	50000
100 ml	60000
200 ml	30000



Significance of the Unit

Key sterile block for antibiotic dry powder vials (250 mg to 5 g range).


Ensures aseptic integrity with HEPA-controlled environment and segregated flows.

High-speed visual inspection (15,000 vials/hour) and automated packaging ensure quality and efficiency.


Controlled storage with humidity regulation maintains product stability and compliance

Historical Financial Highlights


Revenue from operations (INR in Lakhs)




Operating Profit (INR in Lakhs)




Consolidated PAT (INR in Lakhs)



Debt to Equity (x)



Net-worth (INR in Lakhs)





THANK YOU





For further information, please contact:

Company :

Sakar Healthcare Limited
CIN: L24231GJ2004PLC043861
Email – info@sakarhealthcare.com
cs@sakarhealthcare.com

Investor Relations Advisors :

MUFG Intime India Private Limited
A part of MUFG Corporate Markets,
a division of MUFG Pension & Market Service

Mr. Nikunj Seth
nikunj.seth@in.mpms.mufg.com

Mr. Sejal Bhattar
sejal.bhattar@in.mpms.mufg.com

Meeting Request Link